In this Wednesday, July 22, 2020, photo provided by C2N Diagnostics, Matthew Meyer, left, senior proteomics scientist, and Stephanie Knapik, a research associate, work in a lab that analyzes blood samples at the company's facility in the Center for Emerging Technologies in St. Louis. C2N Diagnostics has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also raises concern about the accuracy and impact of such life-altering news. (Jerry Naunheim Jr./C2N Diagnostics via AP)
Follow @bleonardcns
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
